Pros and Cons of Early Chemohormonal Therapy

Get Permission

There is considerable debate about moving chemohormonal therapy to an earlier point in the treatment of prostate cancer, at the time of initial diagnosis of metastases, according to Dr. Yu. In the pro column, “You might hit those de novo testosterone-independent clones if they exist.” Additionally, if one waits until the time of progression, some patients may be too frail to receive chemotherapy.

“The cons: a lot of people, admittedly like myself, thought there was potential for failure because when you give people [androgen-depriation therapy], it takes the cells out of the cell cycle. You get cell-cycle arrest, and your chemotherapy doesn’t do anything except add toxicity. In addition, we have data in breast cancer that shows we don’t do them together.” Furthermore, “some patients respond for a long period of time with initial [androgen-deprivation therapy] and may die of other causes and don’t even need chemotherapy. So why introduce that toxicity? That’s the debate.” ■

Related Articles

Studies Help Refine Management of Prostate Cancer

Several studies reported at this year’s ASCO Annual Meeting address gray areas in the management of prostate cancer, according to Evan Y. Yu, MD, Associate Professor at the University of Washington and the Seattle Cancer Care Alliance. “In prostate cancer, probably the most excitement has happened...




By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.